BioMarin Pharmaceutical (HAM:BM8) Total Equity: €5,373 Mil (As of Mar. 2026)


HAM:BM8 BioMarin Pharmaceutical Inc HAM:BM8
75 GF Score
Price €50.90
GF Value €74.10
! 3 Warning Signs
View Full Analysis

What is BioMarin Pharmaceutical Total Equity?

BioMarin Pharmaceutical HAM:BM8 -2.00% 75 Total Equity is €5,373 Mil as of Mar. 2026. GuruFocus rates HAM:BM8 with a GF Score™ of 75/100 and a GF Value™ of €74.10. The stock has 3 warning signs investors should review.

BioMarin Pharmaceutical's total equity for the quarter that ended in Mar. 2026 was €5,373 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

BioMarin Pharmaceutical Total Equity Historical Data

* Premium members only.

The historical data trend for BioMarin Pharmaceutical's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioMarin Pharmaceutical Total Equity Chart

BioMarin Pharmaceutical Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3,775.12 4,345.38 4,540.57 5,403.38 5,198.30

BioMarin Pharmaceutical Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5,358.95 5,225.51 5,160.32 5,198.30 5,373.47
HAM:BM8
75GF Score
BioMarin Pharmaceutical Inc HAM:BM8
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioMarin Pharmaceutical Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

BioMarin Pharmaceutical's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=6485.295-1286.998
=5,198

BioMarin Pharmaceutical's Total Equity for the quarter that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=7431.229-2057.756
=5,373

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of €5,373 Mil mean?
BioMarin Pharmaceutical (HAM:BM8) has a Total Equity of €5,373 Mil as of Mar. 2026. The total amount of equity as record on a company's balance sheet. View historical data for BioMarin Pharmaceutical and its competitors.
Is BioMarin Pharmaceutical's Total Equity too high?
BioMarin Pharmaceutical's current Total Equity is €5,373 Mil. Overall, BioMarin Pharmaceutical has a GF Score™ of 75/100, reflecting its overall financial health beyond just this single metric.
How does BioMarin Pharmaceutical's Total Equity compare to CYTK and ARWR?
BioMarin Pharmaceutical's Total Equity of €5,373 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Biotechnology company?
A good Total Equity depends on the Biotechnology industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for BioMarin Pharmaceutical and its competitors. BioMarin Pharmaceutical's current Total Equity is €5,373 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioMarin Pharmaceutical stock overvalued right now?
BioMarin Pharmaceutical (HAM:BM8) has a current Total Equity of €5,373 Mil. The stock's GF Value™ is €74.10, compared to a current price of €50.90 — trading 31.3% below its estimated fair value. The current Total Equity is €5,373 Mil. BioMarin Pharmaceutical's overall GF Score™ is 75/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For BioMarin Pharmaceutical (HAM:BM8), the current Total Equity is €5,373 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BioMarin Pharmaceutical (HAM:BM8) Overvalued in 2026?

Based on GuruFocus' analysis, BioMarin Pharmaceutical stock appears to be undervalued. The current stock price of €50.90 is trading 31.3% below its estimated GF Value™ of €74.10.

Key valuation signals for HAM:BM8:

  • Total Equity: €5,373 Mil
  • GF Value™: €74.10 vs. price of €50.90 (31.3% below fair value)
  • GF Score™: 75/100 with 3 warning signs

No single metric tells the full story. See the HAM:BM8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BioMarin Pharmaceutical Business Description

Address 770 Lindaro Street, San Rafael, CA, USA, 94901
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.
75GF Score

Get the complete analysis for HAM:BM8

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€50.90
Price
€74.10
GF Value